CompletedNot Applicable

Copeptin After an Oral Stimulation With Macimorelin in Healthy Volunteers

Switzerland28 participantsStarted 2019-03-07

Plain-language summary

This study investigates stimulation of the posterior pituitary gland by oral Macimorelin (a ghrelin receptor Agonist) to be a novel diagnostic test in the polyuria-polydipsia syndrome.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * No medication except hormonal contraception Exclusion Criteria: * Body Mass Index (BMI) \> 40kg/m2 or BMI \< 18.5 kg/m2 * participation in a trial with investigational drugs within 30 days * vigorous physical exercise within 24 hours before the study participation * Alcohol intake within 24 hours before study participation * pregnancy and breastfeeding * Evidence of disordered drinking habits and diuresis defined as polyuria \>50ml/kg body weight/24h and polydipsia \>3l /24h * a prolonged QT interval (QTc \>500 ms) or concomitant treatment with drugs that prolong the QT/QTc. * Intention to become pregnant during the course of the study * Known allergy towards Macimorelin

What they're measuring

Change in Copeptin value (pmol/l), after intake of Macimorelin of 0.5mg/kg body weight

Timeframe: baseline blood exam (timepoint 0) and further blood collections after 30, 45, 60, 90 and 120 minutes after baseline blood collection

Trial details

NCT IDNCT03844217

SponsorUniversity Hospital, Basel, Switzerland

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-07-16

View on ClinicalTrials.gov More Polyuria-polydipsia Syndrome trials